PALISADE BIO INC (PALI)       3.69  -0.19 (-4.9%)

3.69  -0.19 (-4.9%)

US6963891055 - Common Stock


Fundamental Rating

2

Taking everything into account, PALI scores 2 out of 10 in our fundamental rating. PALI was compared to 254 industry peers in the Pharmaceuticals industry. PALI has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PALI is valued expensive at the moment.




Profitability

Profitability Rating

1

PALI has negative profitability rations, so we won't be analyzing them here.
PALI has a Return On Assets of -58.20%. This is below the industry average of -41.33%.

PALI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of PALI.
VS Industry

ROA (-58.2%) VS Industry: 36% outperformed.

-1,292.14
111.39

Valuation

Valuation Rating

3

With a price book ratio of 0.46, PALI is valued rather cheaply.
When comparing the price book ratio of PALI to the average industry price book ratio of 1.46, PALI is valued rather cheaply. PALI is also cheaper than 87% of the companies listed in the same industry.
When comparing the Enterprise Value to EBITDA ratio of PALI to the average industry ratio of 3.40, PALI is valued rather cheaply. PALI is also cheaper than 83% of the companies listed in the same industry.

PALI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PALI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (0.46) VS Industry: 87% outperformed.

323.96
0.11

Enterprise Value/ EBITDA (0.49) VS Industry: 83% outperformed.

242.04
0.01

Growth

Growth Rating

4

PALI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.04%, which is quite impressive.
Based on estimates for the next 5 years, PALI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.02% on average per year.

The Revenue for PALI has decreased by -100.00% in the past year. This is quite bad

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 87.04% 87.5% 39.74% 25.21% 14.02%
RevenueN/A N/A -100% N/A N/A N/A N/A

Health

Health Rating

3

PALI has a Current Ratio of 4.31. This indicates that PALI is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 4.31 indicates that PALI has no problem at all paying its short term obligations.
PALI has a Current Ratio comparable to the industry average, which is at 3.52.
The Quick Ratio is in line with the industry averages, which is at 2.89.

The Debt to Equity ratio of PALI is in line with the industry averages.
PALI has an Altman-Z score of -10.40. This is a bad value and indicates that PALI is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.57, PALI is in worse financial state than most of its industry peers. 88% of its industry peers have a better Altman-Z score.
The Piotroski-F score of PALI is 3.00. This is a low score and indicates issues in the health and profitability of PALI.
VS Industry

Debt/Equity (0) VS Industry: 54% outperformed.

59.36
0.00

Quick Ratio (4.31) VS Industry: 59% outperformed.

-2.73
76.82

Current Ratio (4.31) VS Industry: 57% outperformed.

0.09
76.82

Altman-Z (-10.4) VS Industry: 12% outperformed.

-220.45
104.30

Dividend

Dividend Rating

0

PALI does not give a dividend.

PALI Daily chart

PALISADE BIO INC3.69

NASDAQ:PALI (11/30/2022, 11:00:07 AM)-0.19 (-4.9%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Pharmaceuticals
Earnings (Last) 11-14 2022-11-14/bmo Earnings (Next) 03-16 2023-03-16
Ins Owners 14.36% Inst Owners 545.06%
Market Cap 5.69M Analysts 82.5
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 0.46
EV/EBITDA 0.49
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y 87.04% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -119.05%
EPS Next Y 87.5% EPS Next 2Y 39.74%
EPS Next 3Y 25.21% EPS Next 5Y 14.02%
Revenue growth 1Y -100% Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 4.31 Quick Ratio 4.31
Altman-Z -10.4 F-Score 3
Debt/Equity 0 WACC 8.71%
ROIC/WACC N/A
Profitability
ROA -58.2% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA